ClinicalTrials.gg
RecruitingNCT06892145Updated Dec 22, 2025

Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE

A Phase 1 interventional study of MC-1-50 in Systemic Lupus Erythematosus (SLE) and Refractory, sponsored by Chongqing Precision Biotech Co., Ltd. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Chongqing Precision Biotech Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.

Planned enrollment
207th of 245
12 · median 36
Started
2025
with 61 others
Phase 1
109 of 266
85 open now
Primary completion
2026-05
later than 46 of 190 live
Registered
164th of 266
by date

Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 207th largest by planned enrollment of the 245 interventional ones that give a count, is one of 62 that started in 2025, is one of 109 in phase 1, reaches primary completion later than 46 of the 190 other live ones, and was the 164th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Lupus Erythematosus, Systemic with a site in China, or all of them as a file.
02

Study summary

This is a single-arm, open, dose-increasing and dose-expanding phase I clinical trial to investigate the safety, tolerability and cytodynamic characteristics of MC-1-50 cell preparation, and to preliminatively observe the efficacy of MC-1-50 cell preparation in patients with refractory SLE, and to explore the applicable dose regimen for phase II clinical trials.

Read the detailed description

Based on the specific CD19-targeting CAR-T developed by PrimeCARTM platform, the cell preparation time is about 3 days, which can greatly shorten the waiting time of patients, improve production efficiency and reduce production costs.At the same time, MC-1-50 products contain a high proportion of T naive cells, which can play a therapeutic role at a very low infusion dose and improve safety.

In this study, three dose groups were composed of 0.3×10\^5/kg, 1×10\^5/kg and 3×10\^5/kg CAR-positive cells, respectively.All subjects received only one infusion of MC-1-50 cells.

03

Conditions studied

  • Systemic Lupus Erythematosus (SLE)
  • Refractory

Keywords

  • CAR T-Cell therapy
  • Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient or their guardian agrees to participate in this clinical trial and sign the ICF, indicating their understanding of the purpose and procedures of this clinical trial and willingness to participate in the study;
  2. Age ≥ 18 years old , gender not limited;
  3. Patients diagnosed with SLE according to the 2019 EULAR/ACR classification criteria,And by hydroxychloroquine, sufficient (≥1mg/kg/d prednisone or equivalent amount of other hormones), to less than 2Treatment with (including cyclophosphamide, motecophanate, azathioprine, methotrexate, cyclosporine, tacrolimus, sirolimus, leflunomide, etc.), and at least one approved biological agent (including titacept, Beliuzumab, etc.), with a total duration of treatment ≥3 months, still in a disease active state, or unable to tolerate conventional therapy;
  4. SLEDAI-2K score ≥7 points;
  5. Autoantibody test results are positive: ANA antibody positive and/or serum anti-DSDNA positive;
  6. Adequate renal, hepatic, pulmonary and cardiac function defined as:

    1. Cardiac function: Echocardiography indicates ≥ 50%;
    2. Renal function: serum creatinine ≤ 2.0 × , or rate ≥ 60ml/min (Cockcroft Gault formula);
    3. Hepatic function: and AST ≤ 3.0 × ULN (may be relaxed to ≤ 3.0 × ULN in cases of combined liver infiltration);
    4. Total ≤ 2.0 × ULN (Gilbert syndrome requires total bilirubin ≤ 3.0 × ULN);
    5. Pulmonary function: Blood oxygen saturation is ≥ 92% in non oxygen state.
  7. No serious mental disorders;
  8. Meet standards for apheresis or venous blood collection, and no other cell collection ;
  9. Women of childbearing age who have a negative blood pregnancy test and all subjects agree to use reliable and effective methods (excluding safe period contraception) for contraception within one year after receiving MC-1-50 cell infusion from the time of signing the form. Including but not limited to: abstinence, implantable progestogen contraceptives that can inhibit ovulation; Intrauterine device (IUD); Intrauterine hormone release system; Spouse vasectomy; Compound hormone contraceptives that can inhibit ovulation (oral, vaginal, and transdermal); Progesterone contraceptives (oral or injectable) that can inhibit ovulation; When male subjects have sex with fertile women, they must agree to use barrier contraception (such as condom plus spermicidal foam/gel/film/emulsion/suppository). At the same time, participants should commit not to donate eggs (oocytes, oocytes) or sperm for assisted reproduction within one year after cell infusion.

Exclusion criteria

Exclusion Criteria:

  1. There were severe active central nervous system lupus that required therapeutic intervention at the time of screening;
  2. Acute severe nephritis: had or was undergoing renal replacement therapy within 3 months prior to reinfusion, or had significant renal deterioration that the investigator believed was likely to cause the subject to require high doses of (prednisone ≥1mg/kg/ day or equivalent of other hormones), cyclophosphamide, or mycophanate during the first 3 months of the study;Clinical stable lupus nephritis that can be controlled during screening can be considered;
  3. There were other lupus crises that were not controlled at the time of screening;
  4. Individuals who have received CAR-T therapy or other gene modified cell therapies;
  5. Combined with other diseases requiring systemic treatment;
  6. or HBcAb positive and HBV DNA test greater than the normal range; antibody positive and HCV RNA detection greater than the normal range; antibody positive;Treponema pallidum antibody positive;
  7. Suffered from any of the following heart diseases:

    1. (NYHA) stage III or IV congestive heart failure;
    2. Within the 6 months prior to enrollment, there has been a myocardial infarction, or a coronary artery bypass grafting (CABG) or stent implantation surgery has been performed;
    3. History of ventricular arrhythmias requiring treatment or unexplained syncope (excluding cases caused by vasovagal or dehydration);
    4. History of severe non-ischemic cardiomyopathy;
  8. Uncontrollable infection in the 1 weeks before enrollment;
  9. History of solid organ transplantation or hematopoietic stem cell transplantation prior to screening;
  10. Cerebrovascular accident or seizure occurred within 6 months prior to screening;
  11. Deep vein or deep artery embolism event within the past 6 months prior to screening;
  12. history of malignant neoplasms (other than tumors with no active lesion and ending treatment > 2 years ago, and adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical surgery, and ductal carcinoma in situ after radical surgery);
  13. (attenuated) ≤ 4 weeks prior to screening;
  14. Have participated in other clinical trials within one month or five drug half lives (whichever is shorter) before enrollment;
  15. Women who are pregnant or breastfeeding, and male or female subjects who plan to have children within 1 year after receiving MC-1-50 cell infusion;
  16. Other situations considered by the investigator to be unsuitable to participate in the study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    MC-1-50

    Patients will be be treated with CD19 CAR- T cells

    Biological: MC-1-50

Interventions

  • BiologicalMC-1-50

    A single infusion of CD19 CAR-T cells will be administered intravenously after lymphodepletion chemotherapy

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Dose-limiting toxicity after CD19 CAR-T cell infusion

    Time frame: 1 month

  2. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    The incidence of adverse events after CAR-T cell infusion was assessed by the National Cancer Institute\'s Common Terminology Criteria for Adverse Events (CTCAE, version 5.0)

    Time frame: 1 month

Secondary outcomes

  1. Validity endpoint of MC-1-50 cells [Efficacy]

    3M SRI-4 response rate, 6M LLDAS, DORIS response rate,SLEDAI-2K score, PGA, and BILAG-2004 change from baseline

    Time frame: 3 months

  2. AUCS of MC-1-50 cells [Cell dynamics]

    AUCS is defined as the area under the curve in 28/90 days

    Time frame: 3 months

  3. CMAX of MC-1-50 cell preparation [Cell dynamics]

    CMAX is defined as the highest concentration of MC-1-50 cells expanded in peripheral blood

    Time frame: 3 months

  4. TMAX of MC-1-50 cell preparation[Cell dynamics]

    TMAX is defined as the time to reach the highest concentration

    Time frame: 3 months

  5. Pharmacodynamics of MC-1-50 cell preparation[Cell dynamics]

    The clearance degree of CD19-positive B cells in peripheral blood was detected by flow cytometry at the visit points specified in the research protocol

    Time frame: 3 months

  6. Immunogenicity of pCAR-19B cells

    The anti-CAR antibody was detected by ELISAt the visit points specified in the research protocol

    Time frame: 3 months

Other outcomes

  1. Response rate after MC-1-50 infusion [Long-term Efficacy]

    The DORIS response rate, LLDAS maintenance rate, and SRI-4 response rate at the remaining sites after reinfusion when other drugs (including hormones, hydroxychloroquine, immunosuppressants, and biologics) were discontinued.And changes from baseline in SLEDAI-2K scores, PGA scores, BILAG-2004 scores, and serological indicators, including anti-DSDNA, anti-nuclear antibodies, and complement C3 and C4 levels

    Time frame: 2 years

  2. The rebuilding of the immune system

    Proportion of B-cell subtypes at each site and their association with reduced disease activity

    Time frame: 2 years

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for May 2026, 10 months after the start.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 10 months is below that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2025
First posted
Mar 24, 2025
StartActual
Jun 12, 2025
Primary completionEst.
May 4, 2026
CompletionEst.
Feb 16, 2028
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06892145
Responsible party
Sponsor
First posted
Mar 24, 2025
Start date
Jun 12, 2025
Primary completion
May 4, 2026 (estimated)
Completion
Feb 16, 2028 (estimated)
Last update
Dec 22, 2025

Study contacts

Jing Xue, M.D.
Contact
xuej@zju.edu.cn
+8613858121751
Zhu Chen, M.D.
Contact
doczchen@gmail.com
+8613956963042

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion